Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib + Dacarbazine + Capecitabine in Medullary Thyroid Carcinoma
NCT00354523Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2004
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in medullary thyroid carcinoma (MTC), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2004; status: terminated.
02
Drugs
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT00354523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354523.